Trial

NCT05398263

Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
Amgen
Condition
Asthma
Intervention
Tezepelumab
Why stopped
The study was discontinued due to slow recruitment, resulting from evolving clinical practices that reduced the use of maintenance oral corticosteroids for severe asthma treatment. The termination decision was not related to safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-18